Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48 + Xindilimab + SOX vs SOX in perioperative HER2-positive locally advanced gastric cancer (Phase II)
ChiCTR2500108466Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of disitamab vedotin, sintilimab, oxaliplatin and tegafur in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: pathological complete response rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
disitamab vedotinsintilimaboxaliplatintegafur
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500108466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108466.